143 related articles for article (PubMed ID: 38662205)
21. Efficacy of cytarabine, aclarubicin and granulocyte colony-stimulating factor (CAG) regimen compared to FLAG regimen for adult patients with relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Li X; Liu L; Zhang Y; Qu Q; Yao Y; Wang T; Jiao W; Wu D
Leuk Res; 2015 Aug; ():. PubMed ID: 26360548
[TBL] [Abstract][Full Text] [Related]
22. Early T-Cell Precursor Leukemia: A High-Risk Subtype of Acute Lymphoblastic Leukemia, Single Center Experience in Jordan.
Halahleh K; Muradi I; Khalil MZ; Halahleh L; Sughayer M; Kamal N; Sultan I; Alrabi K
Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):e411-e419. PubMed ID: 37730482
[TBL] [Abstract][Full Text] [Related]
23. Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study.
You L; Liu Y; Mai W; Xie W; Zhou D; Mao L; Chen L; Zhou X; Ma L; Zheng X; Wei J; Lou Y; Ye X; Tong H; Jin J; Meng H
Eur J Cancer; 2024 May; 202():113979. PubMed ID: 38471289
[TBL] [Abstract][Full Text] [Related]
24. [Comparison of Therapeutic Efficacy between Hypomenthylating Agents Combined with Venetoclax and Half Dose Priming Regimen in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia].
Xu MZ; Qiao M; Sun AN; Wu DP; Xue SL; Zhou HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1631-1636. PubMed ID: 36476881
[TBL] [Abstract][Full Text] [Related]
25. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.
Jain N; Lamb AV; O'Brien S; Ravandi F; Konopleva M; Jabbour E; Zuo Z; Jorgensen J; Lin P; Pierce S; Thomas D; Rytting M; Borthakur G; Kadia T; Cortes J; Kantarjian HM; Khoury JD
Blood; 2016 Apr; 127(15):1863-9. PubMed ID: 26747249
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy and safety of Venetoclax in the treatment of 25 patients with recurrent hematologic malignancies after an allogeneic hematopoietic stem cell transplantation].
Chen X; Liu ZY; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2022 Jul; 43(7):542-549. PubMed ID: 36709130
[No Abstract] [Full Text] [Related]
27. The role of daratumumab in relapsed/refractory CD38 positive acute leukemias-case report on three cases with a literature review.
Prejzner W; Piekoś O; Bełdzińska K; Sadowska-Klasa A; Zarzycka E; Bieniaszewska M; Lewandowski K; Zaucha JM
Front Oncol; 2023; 13():1228481. PubMed ID: 37941558
[TBL] [Abstract][Full Text] [Related]
28. Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review.
Zhao Y; Jiang S; Tang Y; Zhao L
Int J Hematol; 2023 Oct; 118(4):483-488. PubMed ID: 37269505
[TBL] [Abstract][Full Text] [Related]
29. Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia.
Canaani J; Frisch A; Pollyea DA; Schwartz M; Aumann S; Ganzel C; Haran A; Even-Zohar NG; Shaulov A; Vainstein V; Moshe Y; Ofran Y; Wolach O; Nachmias B
Eur J Haematol; 2023 Sep; 111(3):365-372. PubMed ID: 37254665
[TBL] [Abstract][Full Text] [Related]
30. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study.
Candoni A; Lazzarotto D; Ferrara F; Curti A; Lussana F; Papayannidis C; Del Principe MI; Bonifacio M; Mosna F; Delia M; Minetto P; Gottardi M; Fracchiolla N; Mancini V; Forghieri F; Zappasodi P; Cerrano M; Vitale A; Audisio E; Trappolini S; Romani C; Defina M; Imbergamo S; Ciccone N; Santoro L; Cambò B; Iaccarino S; Dargenio M; Aprile L; Chiaretti S; Fanin R; Pizzolo G; Foà R
Am J Hematol; 2020 Dec; 95(12):1466-1472. PubMed ID: 32777149
[TBL] [Abstract][Full Text] [Related]
31. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
32. A retrospective comparison of salvage intensive chemotherapy
Park S; Kwag D; Kim TY; Lee JH; Lee JY; Min GJ; Park SS; Yahng SA; Jeon YW; Shin SH; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Kim HJ
Ther Adv Hematol; 2022; 13():20406207221081637. PubMed ID: 35340720
[TBL] [Abstract][Full Text] [Related]
33. Early T-Cell Precursor Acute Lymphoblastic Leukemia and T/Myeloid Mixed Phenotype Acute Leukemia Possess Overlapping Characteristics and Both Benefit From CAG-Like Regimens and Allogeneic Hematopoietic Stem Cell Transplantation.
Liu S; Cui Q; Dai H; Song B; Cui W; Xue S; Qiu H; Miao M; Jin Z; Li C; Fu C; Wang Y; Sun A; Chen S; Zhu X; Wu D; Tang X
Transplant Cell Ther; 2021 Jun; 27(6):481.e1-481.e7. PubMed ID: 33785365
[TBL] [Abstract][Full Text] [Related]
34. Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.
Zhu HH; Jiang H; Jiang B; Lu J; Jiang Q; Bao L; Zhang XH; Qin YZ; Huang XJ
Leuk Lymphoma; 2013 Nov; 54(11):2452-7. PubMed ID: 23432721
[TBL] [Abstract][Full Text] [Related]
35. Chidamide, Decitabine, Cytarabine, Aclarubicin, and Granulocyte Colony-stimulating Factor Therapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Study from a Single-Center.
Kong FC; Qi L; Zhou YL; Yu M; Huang WF; Li F
Curr Med Sci; 2023 Dec; 43(6):1151-1161. PubMed ID: 38057538
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy and Survival of Venetoclax Based Regimen in the Treatment of Acute Myeloid Leukemia].
Kong FC; Qi L; Huang WF; Yu M; Zhou YL; Ji DX; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1676-1683. PubMed ID: 38071045
[TBL] [Abstract][Full Text] [Related]
37. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
[TBL] [Abstract][Full Text] [Related]
38. Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Gibson A; Trabal A; McCall D; Khazal S; Toepfer L; Bell DH; Roth M; Mahadeo KM; Nunez C; Short NJ; DiNardo C; Konopleva M; Issa GC; Ravandi F; Jain N; Borthakur G; Kantarjian HM; Jabbour E; Cuglievan B
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008312
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of G-CSF, low-dose cytarabine and aclarubicin in combination with l-asparaginase, prednisone in the treatment of refractory or relapsed acute lymphoblastic leukemia.
Zhou K; Song Y; Zhang Y; Wei X; Fu Y; Yu F; Zhou H; Liu X; Zhou J; Fang B
Leuk Res; 2017 Nov; 62():29-33. PubMed ID: 28982056
[TBL] [Abstract][Full Text] [Related]
40. Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial.
Suo X; Zheng F; Wang D; Zhao L; Liu J; Li L; Zhang Z; Zhang C; Li Y; Yang S; Zhao X; Shi R; Wu Y; Jiao Z; Song J; Zhang L; Lu X; Yuan L; Gao S; Zhang J; Zhao X; Bai G; Liu K; Mi Y
Exp Hematol Oncol; 2023 May; 12(1):45. PubMed ID: 37173750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
